NEW YORK--(BUSINESS WIRE)--Steel Partners Holdings L.P. (together with its affiliates, "Steel†), which beneficially owns approximately 1.3% of the outstanding shares of InMode Ltd. (Nasdaq: INMD) ("InMode†or the "Company†), today issued a public letter to the Company's shareholders. The full text of the letter is below. January 28, 2026 Fellow Shareholders, We are writing to make you aware that we have expressed interest to InMode's leadership in pursuing an acquisition by Steel Partners of 51. ...

Core Insights - Sanuwave Health Inc. (SNWV) shares experienced a significant increase of 9.1%, closing at $40.82, following a trading session with higher-than-average volume [1] - The rise in shares is linked to the company reporting record preliminary Q3 2025 revenues between $11.4 million and $11.6 million, indicating a year-over-year increase of 22% to 24% and a sequential increase of 12% to 14% [2] - The company is projected to report quarterly earnings of $0.37 per share, reflecting a year-over-year growth of 105.7%, with expected revenues of $12.37 million, up 32.2% from the previous year [3] Revenue and Earnings Estimates - The consensus EPS estimate for Sanuwave Health has been revised 35.7% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - September marked the highest revenue month in Sanuwave's history, contributing to positive investor sentiment and indicating sustained demand [2] Industry Context - Sanuwave Health is categorized under the Zacks Medical - Products industry, where InMode (INMD) is another player, having closed 0.5% higher at $15.23 [5] - InMode's consensus EPS estimate has remained unchanged at $0.32, representing a decline of 54.3% from the previous year, and it currently holds a Zacks Rank of 3 (Hold) [6]

Company Overview - Envista (NVST) is expected to report a year-over-year increase in earnings, with a consensus estimate of $0.24 per share, reflecting a change of +118.2% [3] - Revenues are anticipated to be $641.45 million, which is a 1.3% increase from the previous year [3] Earnings Expectations - The earnings report is scheduled for July 31, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] Earnings Surprise Prediction - The Most Accurate Estimate for Envista is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.65%, suggesting a bearish outlook from analysts [12] - Despite the negative Earnings ESP, Envista holds a Zacks Rank of 2, complicating predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Envista exceeded the expected earnings of $0.20 per share, achieving $0.24, which was a surprise of +20.00% [13] - Over the past four quarters, Envista has beaten consensus EPS estimates three times [14] Industry Context - InMode (INMD), another player in the Zacks Medical - Products industry, is expected to post earnings of $0.43 per share, indicating a year-over-year change of +26.5% [18] - InMode's revenues are projected to be $95.5 million, up 10.5% from the previous year [18] - The consensus EPS estimate for InMode has been revised down by 9.8% over the last 30 days, and it currently has an Earnings ESP of 0% with a Zacks Rank of 5 [19]

Core Viewpoint - DOMA Perpetual Capital Management LLC urges InMode Ltd.'s Board to resume and accelerate stock buybacks and replace CEO Moshe Mizrahy due to concerns over capital allocation strategy and declining stock performance [1][2][3]. Capital Allocation Strategy - The letter emphasizes the need for the Board to act on behalf of shareholders by resuming the share repurchase program and returning cash to shareholders, as the current cash on the balance sheet is not generating earnings [3][4]. - InMode's stock price is viewed as undervalued, with approximately 60% of its market cap in cash, and the company maintains no debt while generating free cash flow [4][7]. CEO Performance and Leadership Concerns - CEO Moshe Mizrahy's management style is criticized as reckless and antagonistic, contributing to the company's underperformance and negative public perception [2][5]. - The letter highlights that Mizrahy has consistently lowered guidance and made poor management decisions, such as firing the US Head of Sales before a critical quarter [5][6]. Financial Performance and Valuation - As of May 7, 2025, InMode's market capitalization, excluding cash, is approximately $375 million, which does not reflect the company's strong business fundamentals, including gross margins near 80% [7][8]. - The letter argues that the current valuation is disconnected from the reality of InMode's business, which includes valuable assets like inventory, global distribution, and unique intellectual property [7][8].

Core Viewpoint - InMode Ltd. is set to release its financial results for the first quarter of 2025 on April 28, 2025, with preliminary revenue expectations ranging from $77.2 million to $77.5 million and a projected non-GAAP gross margin of 78% to 79% [6][2]. Financial Results - The company anticipates first quarter 2025 revenue to be between $77.2 million and $77.5 million [6]. - The projected non-GAAP gross margin for the same period is expected to be in the range of 78% to 79% [6]. - For the full year 2025, InMode expects revenue to be between $395 million and $405 million [6]. Conference Call Details - A conference call to discuss the first quarter 2025 financial results will take place on April 28, 2025, at 8:30 a.m. Eastern Daylight Time [3]. - Key management personnel, including the CEO, CFO, and CTO, will present during the call [3]. - Participants are encouraged to pre-register for the call to receive unique dial-in information [4]. Company Overview - InMode is recognized as a leading global provider of innovative medical technologies, focusing on devices that utilize novel radio frequency technology [6][7]. - The company aims to enhance surgical procedures and improve existing treatments across various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [6][7].

Core Insights - The article discusses the author's previous recommendation of InMode (NASDAQ: INMD) as a Hold due to concerns over management's capital allocation efficiency [1]. Group 1 - The author has over 10 years of experience in analyzing and publishing reports on companies in Brazil, Chile, and the United States [1]. - The focus of the author's analysis is primarily on small-cap companies, utilizing a deep value investment approach [1]. - The current strategy involves managing a personal portfolio and that of close friends, emphasizing fundamental analysis [1]. Group 2 - The author seeks U.S. companies with solid capital structures, clear growth potential, and efficient, trustworthy management teams [1].

YOKNEAM, Israel, March 26, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, and Yair Malca, Chief Financial Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 2:15 pm Eastern Time on Tuesday, April 8, and a live webcast of the presentation can be accessed ...

As filed with the Securities and Exchange Commission on September 16, 2024. Registration No. 333-281987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ELEVAI LABS INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 5912 85-1399981 (I.R.S. Employer Identification No. ...

As filed with the Securities and Exchange Commission on September 6, 2024. Registration No. 333-[*] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ELEVAI LABS INC. (Exact name of registrant as specified in its charter) 120 Newport Center Drive, Ste. 250 Newport Beach, CA 92660 (866) 794-4940 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Graydon Ben ...